Agilent Technologies (Oligo GMP)
Boulder, CO
Reagent / Material Supplier
1 confirmed programs
· 1 sponsors
· Last scored 2026-03-15
60.5
Signal Score
✓ FDA Inspections (1)
✓ Clinical Trials (1)
○ SEC Filings
○ Press
Quick Facts: Agilent Technologies (Oligo GMP)
- Signal Score
- 60.5/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Boulder, CO
- Modalities
- Oligonucleotide
- Active CGT Programs
- 1 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-06-18)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
1
Sponsors1
ModalitiesOligonucleotide
1 active programs across 1 sponsors
Modalities: Oligonucleotide
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability
68.0
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Agilent Technologies
SEC FilingsParent: Agilent Technologies
Parent company: Agilent Technologies
Financial assessment: 68.0/100
Capacity
53.0
1 CGT manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Sites: Boulder, CO
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Boulder, CO
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
FDA Inspection History
2025-06
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-06-18 | Frederick, Colorado | Drug Quality Assurance | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Mar 20, 2026
Clinical Activity 1 studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: